Mekkanti Manasa Rekha,
Soumitra Das,
BA.Vishwanath,
- Associate Professor Department of Pharmacy Practice ,Aditya Bangalore Institute of Pharmacy Education and Research, Bangalore Karnataka India
- Student Department of Pharmacy Practice ,Aditya Bangalore Institute of Pharmacy Education and Research, Bangalore Karnataka India
- Chairman Aditya Bangalore Institute of Pharmacy Education and Research, Bangalore Karnataka India
Abstract
Background information: The advancements in medical science continue, but the safety of medication usage is still a question mark and has become a crucial area for researchers to focus on. In the need of the above, various scoring systems and tools have been developed in the area of pharmacy practice research. Prior to the present work, we did a systematic review and meta-analysis and identified two such tools :Medication Fall Risk Score and Evaluation Tool (MFRS), and the Drug Associated Risk Tool (DART) for effective evaluation of risks and prevention of drug-related problems, but the literature regarding their usage is very limited in Indian medical practice, which serves as a major gap. Aim and Objectives: To analyze the impact and outcomes of MFRS (Medication Fall Risk Score and Evaluation Tool) and DART (Drug Associated Risk Tool) in evaluating drug safety and in navigating and minimizing Medication Risks and drug related problems. Methodology: The present study is a Prospective cohort study carried for 12 months from January 2023 to January 2024 in the General Medicine, Obstetrics and Gynaecology departments of Akash Hospital, Bangalore Karnataka, India, all the in-patients admitted with various diseases/disorders with polypharmacy were included and patients not willing to participate in the study were excluded, the data was collected through the personal interviews, case sheets and prescriptions with polypharmacy has been evaluated by using the Medication Risks through MFRS (Medication Fall Risk Score and Evaluation Tool) and DART (Drug Associated Risk Tool) to identify and prevent the risk of drug-related problems and risk factors involved with it, for statistical analysis Prismgraph Pad software version10.2.1 was used. Results: Out of a total of 200 individuals, 45 (22.5%) reported medication allergies, while 52 (26%) acknowledged taking more than three medications daily. Psychological disorders were prevalent in 38 (19%) of the population, with gestational diabetes and anemia during gestation reported by 12 (6%) and 14 (7%) of female participants, respectively. Respiratory diseases were noted in 26 (13%) individuals, while fall history within the last six months was documented in 40 (20%) cases. The application of MFRS and DART tools facilitated comprehensive risk assessment. MFRS identified potential fall risks in 66 (33%) of the population, with recent changes in medications documented in 32 (16%) cases. Antihypertensive drugs were commonly prescribed, with 70 (35%) of participants using them. Additionally, 22 (11%) reported an intake of antithyroid drugs. The DART analysis highlighted medication-related concerns, with 40 (20%) of participants using seven or more prescription medicines regularly. Recent initiation of medication within the last four weeks was reported by 26 (13%) individuals. Symptoms such as drowsiness, high blood pressure, and confusion were prevalent among the population, prompting further evaluation. Furthermore, 28 (14%) of participants were using medications with a narrow therapeutic index, necessitating regular monitoring. Conclusion: This research promotes the significance of medication risk assessment tools in promoting the safety of special populations, emphasizing the need for personalized interventions to optimize therapeutic outcomes while minimizing adverse effects.
Keywords: Medication-related risks, Medication Fall Risk Score and Evaluation Tool (MFRS), Drug Associated Risk Tool (DART),Adverse effects, Poly pharmacy.
References
1. Beezer J, Al Hatrushi M, Husband A, Kurdi A, Forsyth P. Correction to: Polypharmacy definition and prevalence in heart failure: a systematic review. Heart Fail Rev. 2022 Mar;27(2):739. doi: 10.1007/s10741-021-10149-y.
2. Sharma P, Gupta NL, Chauhan HS. Prevalence of polypharmacy: Comparing the status of Indian states. Indian Journal of Community and Family Medicine. 2019 Jan 1;5(1):4-9.
3. Lestari MD, Tamba R, Silaban M. Description of Polypharmacy and Interactions that can Reduce the Effectiveness of Dyspepsia Drugs in patient BPJS with Dyspepsia at the Porsea Regional General Hospital based on Prescriptions Period November-January 2020. International Journal of Health Engineering and Technology (IJHET). 2023 Jan 2;1(5).
4. Halli-Tierney AD, Scarbrough C, Carroll D. Polypharmacy: evaluating risks and deprescribing. American family physician. 2019 Jul 1;100(1):32-8.
5. Shim H, Kim S, Kim M, Kim BS, Jeong E, Lee YJ, Won CW. Older men living with spouse and older women living with spouse and children have lower frailty prevalence: the Korean Frailty and Aging Cohort Study (KFACS). Annals of geriatric medicine and research. 2020 Sep;24(3):204.
6. McMaughan DJ, Oloruntoba O, Smith ML. Socioeconomic status and access to healthcare: interrelated drivers for healthy aging. Frontiers in public health. 2020 Jun 18;8:231.
7. Guizani K, Guizani S. IoT healthcare monitoring systems overview for elderly population. In2020 International Wireless Communications and Mobile Computing (IWCMC) 2020 Jun 15 (pp. 2005-2009). IEEE. DOI: 10.1109/IWCMC48107.2020.9148446
8. Chawla A, Wang C, Patton C, Murray M, Punekar Y, de Ruiter A, Steinhart C. A review of long-term toxicity of antiretroviral treatment regimens and implications for an aging population. Infectious diseases and therapy. 2018 Jun;7:183-95. Doi: https://doi.org/10.1007/s40121-018-0201-6
9. Manfredi R. HIV disease and advanced age: an increasing therapeutic challenge. Drugs & aging. 2002 Sep;19:647-69. https://doi.org/10.2165/00002512-200219090-00003
10. Banerjee S. Determinants of rural-urban differential in healthcare utilization among the elderly population in India. BMC Public Health. 2021 Dec;21:1-8.
11. Orth, L.E., Feudtner, C., Kempe, A. et al. A coordinated approach for managing polypharmacy among children with medical complexity: rationale and design of the Pediatric Medication Therapy Management (pMTM) randomized controlled trial. BMC Health Serv Res 23, 414 (2023). https://doi.org/10.1186/s12913-023-09439-y.
12. Miller M. Medication Management in Patients with Polypharmacy. Rehabilitation Nursing Journal. 2023 Jan 1;48(1):2-4.
13. Silva-Almodóvar A, Nahata MC. Clinical utility of medication-based risk scores to reduce polypharmacy and potentially avoidable healthcare utilization. Pharmaceuticals. 2022 May 28;15(6):681.
14. van der Velde N, Seppala LJ, Hartikainen S, Kamkar N, Mallet L, Masud T, Montero-Odasso M, van Poelgeest EP, Thomsen K, Ryg J, Petrovic M. European position paper on polypharmacy and fall-risk-increasing drugs recommendations in the World Guidelines for Falls Prevention and Management: implications and implementation. European geriatric medicine. 2023 Aug;14(4):649-58.
15. Brünn R, Lemke D, Basten J, Kellermann-Mühlhoff P, Köberlein-Neu J, Muth C, van den Akker M, AdAM Study Group. Use of an electronic medication management support system in patients with polypharmacy in general practice: a quantitative process evaluation of the AdAM trial. Pharmaceuticals. 2022 Jun 17;15(6):759.
16. Lin HW, Lin CH, Chang CK, Chou CY, Yu IW, Lin CC, Li TC, Li CI, Hsieh YW. Economic outcomes of pharmacist-physician medication therapy management for polypharmacy elderly: a prospective, randomized, controlled trial. Journal of the Formosan Medical Association. 2018 Mar 1;117(3):235-43.
17. Rajagopal R, Baltazar MT, Carmichael PL, Dent MP, Head J, Li H, Muller I, Reynolds J, Sadh K, Simpson W, Spriggs S. Beyond AOPs: A mechanistic evaluation of NAMs in DART testing. Frontiers in toxicology. 2022 Mar 7;4:838466.
18. Chen CM, Kuo LN, Cheng KJ, Shen WC, Bai KJ, Wang CC, Chiang YC, Chen HY. The effect of medication therapy management service combined with a national PharmaCloud system for polypharmacy patients. Computer methods and programs in biomedicine. 2016 Oct 1;134:109-19.
19. Michalcova J, Vasut K, Airaksinen M, Bielakova K. Inclusion of medication-related fall risk in fall risk assessment tool in geriatric care units. BMC Geriatr. 2020 Nov 6;20(1):454. doi: 10.1186/s12877-020-01845-9. PMID: 33158417; PMCID: PMC7648375.
20. D Saeed, R Miller, C Darcy, K Miller, K Madden, H McKee, J Agnew, P Crawford, G Carter, C Parsons, Medication-Related Fall (MRF) screening and scoring tool: consensus Delphi validation, International Journal of Pharmacy Practice, Volume 30, Issue Supplement_1, April 2022, Pages i41–i42, https://doi.org/10.1093/ijpp/riac019.057
21. Stämpfli D, Boeni F, Gerber A, Bättig VAD, Weidmann R, Hersberger KE, Lampert ML. Assessing the ability of the Drug-Associated Risk Tool (DART) questionnaire to stratify hospitalised older patients according to their risk of drug-related problems: a cross-sectional validation study. BMJ Open. 2018 Jun 27;8(6):e021284. doi: 10.1136/bmjopen-2017-021284. PMID: 29950469; PMCID: PMC6042600.
22. Kaufmann CP, Stämpfli D, Mory N, Hersberger KE, Lampert ML. Drug-Associated Risk Tool: development and validation of a self-assessment questionnaire to screen for hospitalised patients at risk for drug-related problems. BMJ Open. 2018 Mar 9;8(3):e016610. doi: 10.1136/bmjopen-2017-016610.
23. Pharmaceutical Care Network Europe (PCNE). The definition of drug-related problems. 2009. http://www.pcne.org/sig/drp/drug-related-problems.php (accessed10Nov2016).
24. Foppe van Mil JW, Westerlund T, Brown L, et al. Medical care and drug-relatedproblems:dodoctorsandpharmacistsspeakthesamelanguage?IntJClinPharm2016;38:191–4.10.1007/s11096-016-0249-x
25. Krähenbühl-Melcher A, Schlienger R, Lampert M, et al. Drug-related problems in hospitals: areviewoftherecentliterature.Drug Saf2007;30:379–407.
26. Leendertse AJ, Egberts AC, Stoker LJ, et al. Frequency of and risk factors for preventablemedication-related hospital admissions in the Netherlands. Arch Intern Med 2008;168:1890–6.10.1001/archinternmed.2008.3
27. PirmohamedM,JamesS,MeakinS,etal.Adversedrugreactionsascauseofadmissiontohospital:prospectiveanalysisof18820patients.BMJ2004;329:15–9.10.1136/bmj.329.7456.15
28. Forster AJ, Murff HJ, Peterson JF, et al. The incidence and severity of adverse eventsaffectingpatients after discharge from the hospital. Ann Intern Med 2003;138:161–7. 10.7326/0003-4819-138-3-200302040-00007
Research & Reviews: A Journal of Pharmacology
| Volume | |
| Received | August 9, 2024 |
| Accepted | August 17, 2024 |
| Published | September 5, 2024 |